The research collaboration will use KineMed’s dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways. KineMed R&D executive vice-president Dr. Scott
Using proprietary DNA sequences, the non-invasive molecular diagnostic test will identify the presence or absence of fifteen known high-risk HPV strains. The urine-based HPV-HR DNA test can facilitate
Innovation Network Corporation of Japan, a fund managed by Mitsubishi UFJ Capital, and Daiichi Sankyo have jointly invested in the Orphan Disease Treatment Institute. With the opening of
The WIN Consortium is a network of academic, industry, and patient advocacy organizations that works on bringing personalized cancer care to patients across the world. WIN Consortium delegate
NutriForce SportsOmegafortSCC 1200mg Omega-3 4X Strength has 85% omega-3, and contains essential fatty acids in a single capsule: about 1200mg of omega-3 and more than 1000 mg of
As part of the agreement, Edison will receive $35m upfront and $15m for R&D in exchange for granting development and commercialization rights to DSP. Besides, Edison will be
The company was given licensed exclusive rights to Baxter’s proprietary cell culture-based pandemic influenza vaccines technology for the Japanese market as part of its 2010 December agreement with
The collaboration will focus on metabolomics to develop and test new hardware and software approaches for metabolite detection and identification for environmental and clinical research. The research agreement
The new facility is expected to possess an initial capacity of 90 million units per year in addition to possible expansion of approximately 150 million units. Operations at
As per the agreement, Clinigen will manufacture, register, distribute, and commercialize the product in countries where current marketing authorizations exist, including key European, Asian and Latin American territories.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.